nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—Telmisartan—ABCG2—hematologic cancer	0.0029	0.321	CrCbGaD
Azilsartan medoxomil—Losartan—UGT1A1—hematologic cancer	0.00268	0.296	CrCbGaD
Azilsartan medoxomil—Telmisartan—ABCB1—hematologic cancer	0.00121	0.133	CrCbGaD
Azilsartan medoxomil—Candesartan—ABCB1—hematologic cancer	0.000972	0.108	CrCbGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—hematologic cancer	0.000837	0.00357	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCR7—hematologic cancer	0.000836	0.00356	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL13—hematologic cancer	0.000836	0.00356	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—hematologic cancer	0.000832	0.00354	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL1B—hematologic cancer	0.000795	0.00339	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP3—hematologic cancer	0.000793	0.00338	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL2—hematologic cancer	0.000792	0.00337	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—hematologic cancer	0.000782	0.00333	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—TRH—hematologic cancer	0.000777	0.00331	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR4—hematologic cancer	0.000776	0.00331	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Dasatinib—hematologic cancer	0.000769	0.00102	CcSEcCtD
Azilsartan medoxomil—Nausea—Bexarotene—hematologic cancer	0.000769	0.00102	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Thiotepa—hematologic cancer	0.000768	0.00101	CcSEcCtD
Azilsartan medoxomil—Fatigue—Thiotepa—hematologic cancer	0.000766	0.00101	CcSEcCtD
Azilsartan medoxomil—Nausea—Fludarabine—hematologic cancer	0.000766	0.00101	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Vinblastine—hematologic cancer	0.000766	0.00101	CcSEcCtD
Azilsartan medoxomil—Asthenia—Melphalan—hematologic cancer	0.000765	0.00101	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—hematologic cancer	0.000758	0.00323	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Melphalan—hematologic cancer	0.000754	0.000997	CcSEcCtD
Azilsartan medoxomil—Rash—Nilotinib—hematologic cancer	0.000754	0.000997	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Nilotinib—hematologic cancer	0.000753	0.000996	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRB2—hematologic cancer	0.000753	0.00321	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Irinotecan—hematologic cancer	0.000753	0.000996	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—hematologic cancer	0.000753	0.00321	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—LPAR1—hematologic cancer	0.000752	0.00321	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Etoposide—hematologic cancer	0.000752	0.000995	CcSEcCtD
Azilsartan medoxomil—Rash—Imatinib—hematologic cancer	0.00075	0.000991	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Imatinib—hematologic cancer	0.000749	0.00099	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Mitoxantrone—hematologic cancer	0.000746	0.000986	CcSEcCtD
Azilsartan medoxomil—Asthenia—Lenalidomide—hematologic cancer	0.000743	0.000983	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Thalidomide—hematologic cancer	0.000742	0.000982	CcSEcCtD
Azilsartan medoxomil—Fatigue—Thalidomide—hematologic cancer	0.000741	0.00098	CcSEcCtD
Azilsartan medoxomil—Dizziness—Vinblastine—hematologic cancer	0.000741	0.00098	CcSEcCtD
Azilsartan medoxomil—Rash—Cladribine—hematologic cancer	0.000736	0.000974	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Cladribine—hematologic cancer	0.000736	0.000973	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Gemcitabine—hematologic cancer	0.000733	0.00097	CcSEcCtD
Azilsartan medoxomil—Pruritus—Lenalidomide—hematologic cancer	0.000733	0.000969	CcSEcCtD
Azilsartan medoxomil—Asthenia—Hydroxyurea—hematologic cancer	0.000733	0.000969	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Melphalan—hematologic cancer	0.000729	0.000964	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Gemcitabine—hematologic cancer	0.000726	0.000961	CcSEcCtD
Azilsartan medoxomil—Nausea—Chlorambucil—hematologic cancer	0.000726	0.00096	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—hematologic cancer	0.000722	0.000955	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Carmustine—hematologic cancer	0.000713	0.000943	CcSEcCtD
Azilsartan medoxomil—Nausea—Nilotinib—hematologic cancer	0.00071	0.000939	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Lenalidomide—hematologic cancer	0.000709	0.000937	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Alitretinoin—hematologic cancer	0.000706	0.000934	CcSEcCtD
Azilsartan medoxomil—Nausea—Imatinib—hematologic cancer	0.000706	0.000934	CcSEcCtD
Azilsartan medoxomil—Fatigue—Alitretinoin—hematologic cancer	0.000705	0.000933	CcSEcCtD
Azilsartan medoxomil—Angioedema—Prednisolone—hematologic cancer	0.000705	0.000932	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Hydroxyurea—hematologic cancer	0.000699	0.000924	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Ifosfamide—hematologic cancer	0.000698	0.000923	CcSEcCtD
Azilsartan medoxomil—Fatigue—Ifosfamide—hematologic cancer	0.000697	0.000922	CcSEcCtD
Azilsartan medoxomil—Nausea—Cladribine—hematologic cancer	0.000694	0.000917	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CNR2—hematologic cancer	0.000692	0.00295	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Lenalidomide—hematologic cancer	0.000685	0.000906	CcSEcCtD
Azilsartan medoxomil—Asthenia—Bortezomib—hematologic cancer	0.000684	0.000905	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Cisplatin—hematologic cancer	0.000684	0.000904	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Epirubicin—hematologic cancer	0.000682	0.000902	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Vincristine—hematologic cancer	0.000681	0.0009	CcSEcCtD
Azilsartan medoxomil—Fatigue—Vincristine—hematologic cancer	0.00068	0.000899	CcSEcCtD
Azilsartan medoxomil—Asthenia—Bleomycin—hematologic cancer	0.000679	0.000898	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Cisplatin—hematologic cancer	0.000677	0.000895	CcSEcCtD
Azilsartan medoxomil—Dizziness—Hydroxyurea—hematologic cancer	0.000676	0.000893	CcSEcCtD
Azilsartan medoxomil—Pruritus—Bortezomib—hematologic cancer	0.000675	0.000892	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—hematologic cancer	0.000673	0.00287	CbGpPWpGaD
Azilsartan medoxomil—Rash—Melphalan—hematologic cancer	0.000672	0.000888	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Melphalan—hematologic cancer	0.000671	0.000888	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Dexamethasone—hematologic cancer	0.000671	0.000888	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Betamethasone—hematologic cancer	0.000671	0.000888	CcSEcCtD
Azilsartan medoxomil—Pruritus—Bleomycin—hematologic cancer	0.000669	0.000885	CcSEcCtD
Azilsartan medoxomil—Asthenia—Vinorelbine—hematologic cancer	0.000668	0.000883	CcSEcCtD
Azilsartan medoxomil—Nausea—Vinblastine—hematologic cancer	0.000665	0.00088	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—hematologic cancer	0.000665	0.00283	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Irinotecan—hematologic cancer	0.000663	0.000876	CcSEcCtD
Azilsartan medoxomil—Fatigue—Mitoxantrone—hematologic cancer	0.000662	0.000875	CcSEcCtD
Azilsartan medoxomil—Fatigue—Irinotecan—hematologic cancer	0.000662	0.000875	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—hematologic cancer	0.000662	0.000875	CcSEcCtD
Azilsartan medoxomil—Pruritus—Vinorelbine—hematologic cancer	0.000659	0.000871	CcSEcCtD
Azilsartan medoxomil—Losartan—ALB—hematologic cancer	0.000656	0.0727	CrCbGaD
Azilsartan medoxomil—Rash—Lenalidomide—hematologic cancer	0.000653	0.000864	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Lenalidomide—hematologic cancer	0.000653	0.000863	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Bortezomib—hematologic cancer	0.000652	0.000863	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK1—hematologic cancer	0.000649	0.00277	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Triamcinolone—hematologic cancer	0.000649	0.000858	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Gemcitabine—hematologic cancer	0.000646	0.000854	CcSEcCtD
Azilsartan medoxomil—Fatigue—Gemcitabine—hematologic cancer	0.000645	0.000853	CcSEcCtD
Azilsartan medoxomil—Rash—Hydroxyurea—hematologic cancer	0.000644	0.000852	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Hydroxyurea—hematologic cancer	0.000644	0.000851	CcSEcCtD
Azilsartan medoxomil—Asthenia—Thiotepa—hematologic cancer	0.000638	0.000843	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Vinorelbine—hematologic cancer	0.000637	0.000842	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RHOJ—hematologic cancer	0.000636	0.00271	CbGpPWpGaD
Azilsartan medoxomil—Connective tissue disorder—Prednisone—hematologic cancer	0.000633	0.000837	CcSEcCtD
Azilsartan medoxomil—Nausea—Melphalan—hematologic cancer	0.000633	0.000837	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Doxorubicin—hematologic cancer	0.000631	0.000835	CcSEcCtD
Azilsartan medoxomil—Dizziness—Bortezomib—hematologic cancer	0.00063	0.000834	CcSEcCtD
Azilsartan medoxomil—Pruritus—Thiotepa—hematologic cancer	0.000629	0.000832	CcSEcCtD
Azilsartan medoxomil—Losartan—ABCB1—hematologic cancer	0.000626	0.0693	CrCbGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ARHGEF12—hematologic cancer	0.000623	0.00265	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Etoposide—hematologic cancer	0.00062	0.00082	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—hematologic cancer	0.000619	0.00264	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TGFB1—hematologic cancer	0.000618	0.00263	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Thalidomide—hematologic cancer	0.000617	0.000816	CcSEcCtD
Azilsartan medoxomil—Dizziness—Vinorelbine—hematologic cancer	0.000616	0.000814	CcSEcCtD
Azilsartan medoxomil—Nausea—Lenalidomide—hematologic cancer	0.000615	0.000814	CcSEcCtD
Azilsartan medoxomil—Pruritus—Thalidomide—hematologic cancer	0.000608	0.000804	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Thiotepa—hematologic cancer	0.000608	0.000804	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ARHGEF1—hematologic cancer	0.000607	0.00259	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Hydroxyurea—hematologic cancer	0.000607	0.000802	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Cisplatin—hematologic cancer	0.000602	0.000796	CcSEcCtD
Azilsartan medoxomil—Rash—Bortezomib—hematologic cancer	0.000601	0.000795	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Bortezomib—hematologic cancer	0.000601	0.000794	CcSEcCtD
Azilsartan medoxomil—Rash—Bleomycin—hematologic cancer	0.000597	0.000789	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Bleomycin—hematologic cancer	0.000596	0.000788	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL3—hematologic cancer	0.000595	0.00254	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Carmustine—hematologic cancer	0.000593	0.000783	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTHLH—hematologic cancer	0.000589	0.00251	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Betamethasone—hematologic cancer	0.000588	0.000778	CcSEcCtD
Azilsartan medoxomil—Angioedema—Dexamethasone—hematologic cancer	0.000588	0.000778	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Thalidomide—hematologic cancer	0.000588	0.000778	CcSEcCtD
Azilsartan medoxomil—Dizziness—Thiotepa—hematologic cancer	0.000588	0.000777	CcSEcCtD
Azilsartan medoxomil—Asthenia—Alitretinoin—hematologic cancer	0.000587	0.000776	CcSEcCtD
Azilsartan medoxomil—Rash—Vinorelbine—hematologic cancer	0.000587	0.000776	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Vinorelbine—hematologic cancer	0.000586	0.000775	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Prednisone—hematologic cancer	0.000585	0.000773	CcSEcCtD
Azilsartan medoxomil—Asthenia—Ifosfamide—hematologic cancer	0.00058	0.000767	CcSEcCtD
Azilsartan medoxomil—Pruritus—Alitretinoin—hematologic cancer	0.000579	0.000765	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—hematologic cancer	0.000577	0.00246	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTGER4—hematologic cancer	0.000573	0.00244	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Ifosfamide—hematologic cancer	0.000572	0.000756	CcSEcCtD
Azilsartan medoxomil—Dizziness—Thalidomide—hematologic cancer	0.000569	0.000752	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IFT172—hematologic cancer	0.000567	0.00242	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Bortezomib—hematologic cancer	0.000566	0.000749	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ARHGEF12—hematologic cancer	0.000566	0.00241	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Vincristine—hematologic cancer	0.000566	0.000748	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Carmustine—hematologic cancer	0.000565	0.000747	CcSEcCtD
Azilsartan medoxomil—Nausea—Bleomycin—hematologic cancer	0.000562	0.000743	CcSEcCtD
Azilsartan medoxomil—Rash—Thiotepa—hematologic cancer	0.000561	0.000741	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Thiotepa—hematologic cancer	0.00056	0.000741	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Alitretinoin—hematologic cancer	0.00056	0.00074	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Ifosfamide—hematologic cancer	0.000553	0.000732	CcSEcCtD
Azilsartan medoxomil—Nausea—Vinorelbine—hematologic cancer	0.000553	0.000731	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ARHGEF1—hematologic cancer	0.000551	0.00235	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000551	0.000729	CcSEcCtD
Azilsartan medoxomil—Asthenia—Irinotecan—hematologic cancer	0.000551	0.000728	CcSEcCtD
Azilsartan medoxomil—Asthenia—Mitoxantrone—hematologic cancer	0.000551	0.000728	CcSEcCtD
Azilsartan medoxomil—Fatigue—Etoposide—hematologic cancer	0.000551	0.000728	CcSEcCtD
Azilsartan medoxomil—Dizziness—Carmustine—hematologic cancer	0.000546	0.000722	CcSEcCtD
Azilsartan medoxomil—Rash—Thalidomide—hematologic cancer	0.000542	0.000717	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Thalidomide—hematologic cancer	0.000542	0.000716	CcSEcCtD
Azilsartan medoxomil—Dizziness—Alitretinoin—hematologic cancer	0.000541	0.000715	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Vincristine—hematologic cancer	0.000539	0.000713	CcSEcCtD
Azilsartan medoxomil—Asthenia—Gemcitabine—hematologic cancer	0.000537	0.00071	CcSEcCtD
Azilsartan medoxomil—Dizziness—Ifosfamide—hematologic cancer	0.000535	0.000707	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCR5—hematologic cancer	0.000535	0.00228	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Gemcitabine—hematologic cancer	0.000529	0.0007	CcSEcCtD
Azilsartan medoxomil—Nausea—Thiotepa—hematologic cancer	0.000528	0.000698	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Irinotecan—hematologic cancer	0.000525	0.000695	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Mitoxantrone—hematologic cancer	0.000525	0.000695	CcSEcCtD
Azilsartan medoxomil—Dizziness—Vincristine—hematologic cancer	0.000521	0.000689	CcSEcCtD
Azilsartan medoxomil—Rash—Carmustine—hematologic cancer	0.000521	0.000689	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Carmustine—hematologic cancer	0.00052	0.000688	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL2—hematologic cancer	0.000519	0.00221	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PPEF1—hematologic cancer	0.000519	0.00221	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GNA13—hematologic cancer	0.000516	0.0022	CbGpPWpGaD
Azilsartan medoxomil—Rash—Alitretinoin—hematologic cancer	0.000516	0.000682	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Betamethasone—hematologic cancer	0.000515	0.000682	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Dexamethasone—hematologic cancer	0.000515	0.000682	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Alitretinoin—hematologic cancer	0.000515	0.000681	CcSEcCtD
Azilsartan medoxomil—Angioedema—Prednisone—hematologic cancer	0.000512	0.000678	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Gemcitabine—hematologic cancer	0.000512	0.000677	CcSEcCtD
Azilsartan medoxomil—Nausea—Thalidomide—hematologic cancer	0.000511	0.000675	CcSEcCtD
Azilsartan medoxomil—Rash—Ifosfamide—hematologic cancer	0.00051	0.000674	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Ifosfamide—hematologic cancer	0.000509	0.000674	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—TIAM1—hematologic cancer	0.000508	0.00216	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Irinotecan—hematologic cancer	0.000508	0.000671	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCR4—hematologic cancer	0.000506	0.00216	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Cisplatin—hematologic cancer	0.0005	0.000661	CcSEcCtD
Azilsartan medoxomil—Fatigue—Triamcinolone—hematologic cancer	0.000499	0.00066	CcSEcCtD
Azilsartan medoxomil—Rash—Vincristine—hematologic cancer	0.000497	0.000657	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Vincristine—hematologic cancer	0.000497	0.000657	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Epirubicin—hematologic cancer	0.000496	0.000656	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—hematologic cancer	0.000496	0.00211	CbGpPWpGaD
Azilsartan medoxomil—Connective tissue disorder—Epirubicin—hematologic cancer	0.000495	0.000655	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL17—hematologic cancer	0.000495	0.00211	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—JAK3—hematologic cancer	0.000493	0.0021	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Carmustine—hematologic cancer	0.000491	0.000649	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Methotrexate—hematologic cancer	0.000488	0.000646	CcSEcCtD
Azilsartan medoxomil—Nausea—Alitretinoin—hematologic cancer	0.000486	0.000643	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCR5—hematologic cancer	0.000485	0.00207	CbGpPWpGaD
Azilsartan medoxomil—Rash—Mitoxantrone—hematologic cancer	0.000484	0.00064	CcSEcCtD
Azilsartan medoxomil—Rash—Irinotecan—hematologic cancer	0.000484	0.00064	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Irinotecan—hematologic cancer	0.000484	0.00064	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Mitoxantrone—hematologic cancer	0.000484	0.00064	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CREB1—hematologic cancer	0.000481	0.00205	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Ifosfamide—hematologic cancer	0.00048	0.000635	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Cisplatin—hematologic cancer	0.000477	0.000631	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	0.000474	0.000627	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL13—hematologic cancer	0.000472	0.00201	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCR7—hematologic cancer	0.000472	0.00201	CbGpPWpGaD
Azilsartan medoxomil—Rash—Gemcitabine—hematologic cancer	0.000472	0.000624	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Gemcitabine—hematologic cancer	0.000471	0.000623	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—hematologic cancer	0.000469	0.002	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PIK3R1—hematologic cancer	0.000469	0.002	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GNA13—hematologic cancer	0.000469	0.002	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Vincristine—hematologic cancer	0.000468	0.000619	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—TIAM1—hematologic cancer	0.000461	0.00197	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL3RA—hematologic cancer	0.00046	0.00196	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Doxorubicin—hematologic cancer	0.000459	0.000607	CcSEcCtD
Azilsartan medoxomil—Asthenia—Etoposide—hematologic cancer	0.000458	0.000606	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Doxorubicin—hematologic cancer	0.000458	0.000606	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Epirubicin—hematologic cancer	0.000457	0.000604	CcSEcCtD
Azilsartan medoxomil—Nausea—Mitoxantrone—hematologic cancer	0.000456	0.000603	CcSEcCtD
Azilsartan medoxomil—Nausea—Irinotecan—hematologic cancer	0.000456	0.000603	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000454	0.0006	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000454	0.0006	CcSEcCtD
Azilsartan medoxomil—Fatigue—Dexamethasone—hematologic cancer	0.000453	0.000599	CcSEcCtD
Azilsartan medoxomil—Fatigue—Betamethasone—hematologic cancer	0.000453	0.000599	CcSEcCtD
Azilsartan medoxomil—Pruritus—Etoposide—hematologic cancer	0.000452	0.000597	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Prednisone—hematologic cancer	0.000449	0.000594	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—JAK3—hematologic cancer	0.000447	0.00191	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—hematologic cancer	0.000447	0.0019	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Prednisone—hematologic cancer	0.000445	0.000588	CcSEcCtD
Azilsartan medoxomil—Nausea—Gemcitabine—hematologic cancer	0.000444	0.000587	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RGS2—hematologic cancer	0.000444	0.00189	CbGpPWpGaD
Azilsartan medoxomil—Rash—Cisplatin—hematologic cancer	0.00044	0.000581	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Cisplatin—hematologic cancer	0.000439	0.000581	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—TRH—hematologic cancer	0.000439	0.00187	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—TRIO—hematologic cancer	0.000439	0.00187	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Etoposide—hematologic cancer	0.000437	0.000578	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL13—hematologic cancer	0.000429	0.00183	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCR7—hematologic cancer	0.000429	0.00183	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—LPAR1—hematologic cancer	0.000425	0.00181	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Doxorubicin—hematologic cancer	0.000423	0.000559	CcSEcCtD
Azilsartan medoxomil—Dizziness—Etoposide—hematologic cancer	0.000422	0.000558	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Epirubicin—hematologic cancer	0.000422	0.000558	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—hematologic cancer	0.000419	0.00179	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL3RA—hematologic cancer	0.000418	0.00178	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Prednisolone—hematologic cancer	0.000417	0.000551	CcSEcCtD
Azilsartan medoxomil—Asthenia—Triamcinolone—hematologic cancer	0.000416	0.00055	CcSEcCtD
Azilsartan medoxomil—Nausea—Cisplatin—hematologic cancer	0.000414	0.000548	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HDAC11—hematologic cancer	0.00041	0.00175	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Triamcinolone—hematologic cancer	0.00041	0.000542	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—hematologic cancer	0.000408	0.00174	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RGS2—hematologic cancer	0.000403	0.00172	CbGpPWpGaD
Azilsartan medoxomil—Rash—Etoposide—hematologic cancer	0.000403	0.000532	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Etoposide—hematologic cancer	0.000402	0.000532	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—TRIO—hematologic cancer	0.000399	0.0017	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—TRH—hematologic cancer	0.000399	0.0017	CbGpPWpGaD
Azilsartan medoxomil—Rash—Prednisolone—hematologic cancer	0.000397	0.000525	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Prednisolone—hematologic cancer	0.000397	0.000525	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	0.000396	0.000524	CcSEcCtD
Azilsartan medoxomil—Fatigue—Prednisone—hematologic cancer	0.000395	0.000522	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BCR—hematologic cancer	0.000393	0.00167	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PDE4B—hematologic cancer	0.000391	0.00167	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CNR2—hematologic cancer	0.000391	0.00167	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Doxorubicin—hematologic cancer	0.00039	0.000516	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—LPAR1—hematologic cancer	0.000386	0.00164	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RAC2—hematologic cancer	0.000385	0.00164	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Triamcinolone—hematologic cancer	0.000383	0.000506	CcSEcCtD
Azilsartan medoxomil—Nausea—Etoposide—hematologic cancer	0.000379	0.000502	CcSEcCtD
Azilsartan medoxomil—Asthenia—Dexamethasone—hematologic cancer	0.000377	0.000499	CcSEcCtD
Azilsartan medoxomil—Asthenia—Betamethasone—hematologic cancer	0.000377	0.000499	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Methotrexate—hematologic cancer	0.000375	0.000496	CcSEcCtD
Azilsartan medoxomil—Nausea—Prednisolone—hematologic cancer	0.000374	0.000495	CcSEcCtD
Azilsartan medoxomil—Pruritus—Dexamethasone—hematologic cancer	0.000372	0.000492	CcSEcCtD
Azilsartan medoxomil—Pruritus—Betamethasone—hematologic cancer	0.000372	0.000492	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Methotrexate—hematologic cancer	0.000372	0.000491	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	0.000371	0.00049	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ADCY7—hematologic cancer	0.000368	0.00157	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HDAC10—hematologic cancer	0.000365	0.00156	CbGpPWpGaD
Azilsartan medoxomil—Rash—Triamcinolone—hematologic cancer	0.000365	0.000483	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Triamcinolone—hematologic cancer	0.000365	0.000482	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Dexamethasone—hematologic cancer	0.00036	0.000476	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Betamethasone—hematologic cancer	0.00036	0.000476	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CNR2—hematologic cancer	0.000355	0.00151	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PDE4B—hematologic cancer	0.000355	0.00151	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Epirubicin—hematologic cancer	0.000351	0.000464	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RAC2—hematologic cancer	0.00035	0.00149	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—hematologic cancer	0.000348	0.00148	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Epirubicin—hematologic cancer	0.000348	0.00046	CcSEcCtD
Azilsartan medoxomil—Dizziness—Betamethasone—hematologic cancer	0.000348	0.00046	CcSEcCtD
Azilsartan medoxomil—Dizziness—Dexamethasone—hematologic cancer	0.000348	0.00046	CcSEcCtD
Azilsartan medoxomil—Nausea—Triamcinolone—hematologic cancer	0.000344	0.000455	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	0.000343	0.000454	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ARHGEF12—hematologic cancer	0.000334	0.00142	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ADCY7—hematologic cancer	0.000334	0.00142	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTHLH—hematologic cancer	0.000333	0.00142	CbGpPWpGaD
Azilsartan medoxomil—Rash—Betamethasone—hematologic cancer	0.000331	0.000438	CcSEcCtD
Azilsartan medoxomil—Rash—Dexamethasone—hematologic cancer	0.000331	0.000438	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Betamethasone—hematologic cancer	0.000331	0.000438	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Dexamethasone—hematologic cancer	0.000331	0.000438	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.00033	0.000437	CcSEcCtD
Azilsartan medoxomil—Fatigue—Methotrexate—hematologic cancer	0.00033	0.000436	CcSEcCtD
Azilsartan medoxomil—Asthenia—Prednisone—hematologic cancer	0.000328	0.000434	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ARHGEF1—hematologic cancer	0.000326	0.00139	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Doxorubicin—hematologic cancer	0.000325	0.00043	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTGER4—hematologic cancer	0.000324	0.00138	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Prednisone—hematologic cancer	0.000324	0.000428	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Doxorubicin—hematologic cancer	0.000322	0.000425	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Prednisone—hematologic cancer	0.000313	0.000414	CcSEcCtD
Azilsartan medoxomil—Nausea—Dexamethasone—hematologic cancer	0.000312	0.000413	CcSEcCtD
Azilsartan medoxomil—Nausea—Betamethasone—hematologic cancer	0.000312	0.000413	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Epirubicin—hematologic cancer	0.000309	0.000409	CcSEcCtD
Azilsartan medoxomil—Fatigue—Epirubicin—hematologic cancer	0.000309	0.000408	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL3—hematologic cancer	0.000306	0.0013	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Prednisone—hematologic cancer	0.000303	0.0004	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTHLH—hematologic cancer	0.000302	0.00129	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—hematologic cancer	0.000298	0.00127	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTGER4—hematologic cancer	0.000294	0.00125	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AGRN—hematologic cancer	0.000292	0.00124	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL17—hematologic cancer	0.000292	0.00124	CbGpPWpGaD
Azilsartan medoxomil—Rash—Prednisone—hematologic cancer	0.000289	0.000382	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Prednisone—hematologic cancer	0.000288	0.000381	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCR5—hematologic cancer	0.000287	0.00122	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCR4—hematologic cancer	0.000286	0.00122	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Doxorubicin—hematologic cancer	0.000286	0.000378	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—hematologic cancer	0.000286	0.00122	CbGpPWpGaD
Azilsartan medoxomil—Fatigue—Doxorubicin—hematologic cancer	0.000286	0.000378	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LEF1—hematologic cancer	0.000282	0.0012	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GNA13—hematologic cancer	0.000277	0.00118	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL3—hematologic cancer	0.000276	0.00118	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Methotrexate—hematologic cancer	0.000274	0.000363	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TIAM1—hematologic cancer	0.000272	0.00116	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Prednisone—hematologic cancer	0.000272	0.000359	CcSEcCtD
Azilsartan medoxomil—Pruritus—Methotrexate—hematologic cancer	0.000271	0.000358	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RASGRP1—hematologic cancer	0.000267	0.00114	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL2—hematologic cancer	0.000265	0.00113	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JAK3—hematologic cancer	0.000264	0.00113	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PIK3CA—hematologic cancer	0.000264	0.00112	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Methotrexate—hematologic cancer	0.000262	0.000346	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCR4—hematologic cancer	0.00026	0.00111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—hematologic cancer	0.000257	0.00109	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Epirubicin—hematologic cancer	0.000257	0.00034	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL13—hematologic cancer	0.000253	0.00108	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCR7—hematologic cancer	0.000253	0.00108	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Epirubicin—hematologic cancer	0.000253	0.000335	CcSEcCtD
Azilsartan medoxomil—Dizziness—Methotrexate—hematologic cancer	0.000253	0.000334	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL3—hematologic cancer	0.000251	0.00107	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NCOR2—hematologic cancer	0.00025	0.00107	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL3RA—hematologic cancer	0.000247	0.00105	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CRKL—hematologic cancer	0.000247	0.00105	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Epirubicin—hematologic cancer	0.000245	0.000324	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RASGRP1—hematologic cancer	0.000242	0.00103	CbGpPWpGaD
Azilsartan medoxomil—Rash—Methotrexate—hematologic cancer	0.000241	0.000319	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Methotrexate—hematologic cancer	0.000241	0.000319	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GRB2—hematologic cancer	0.00024	0.00102	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RGS2—hematologic cancer	0.000238	0.00101	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Doxorubicin—hematologic cancer	0.000238	0.000314	CcSEcCtD
Azilsartan medoxomil—Dizziness—Epirubicin—hematologic cancer	0.000237	0.000313	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—hematologic cancer	0.000236	0.00101	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TRH—hematologic cancer	0.000235	0.001	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TRIO—hematologic cancer	0.000235	0.001	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CMA1—hematologic cancer	0.000235	0.001	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Doxorubicin—hematologic cancer	0.000234	0.00031	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SPHK1—hematologic cancer	0.00023	0.000982	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AGO2—hematologic cancer	0.00023	0.000982	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HDAC9—hematologic cancer	0.000228	0.000972	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LPAR1—hematologic cancer	0.000228	0.000972	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Methotrexate—hematologic cancer	0.000227	0.0003	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Doxorubicin—hematologic cancer	0.000227	0.0003	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—H3F3B—hematologic cancer	0.000226	0.000962	CbGpPWpGaD
Azilsartan medoxomil—Rash—Epirubicin—hematologic cancer	0.000226	0.000298	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Epirubicin—hematologic cancer	0.000226	0.000298	CcSEcCtD
Azilsartan medoxomil—Dizziness—Doxorubicin—hematologic cancer	0.000219	0.00029	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—hematologic cancer	0.000218	0.00093	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GRB2—hematologic cancer	0.000218	0.000928	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CSF2—hematologic cancer	0.000214	0.000913	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Epirubicin—hematologic cancer	0.000213	0.000281	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CNR2—hematologic cancer	0.00021	0.000894	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDE4B—hematologic cancer	0.00021	0.000894	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hematologic cancer	0.000209	0.00089	CbGpPWpGaD
Azilsartan medoxomil—Rash—Doxorubicin—hematologic cancer	0.000209	0.000276	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Doxorubicin—hematologic cancer	0.000209	0.000276	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF19—hematologic cancer	0.000208	0.000887	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PRKCG—hematologic cancer	0.000207	0.000882	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—JAK1—hematologic cancer	0.000207	0.000882	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RAC2—hematologic cancer	0.000206	0.00088	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—DKK1—hematologic cancer	0.000205	0.000873	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT5B—hematologic cancer	0.000203	0.000866	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADCY7—hematologic cancer	0.000197	0.000841	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Doxorubicin—hematologic cancer	0.000197	0.00026	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CSF2—hematologic cancer	0.000195	0.000829	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL2RA—hematologic cancer	0.000193	0.000823	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—XIAP—hematologic cancer	0.000192	0.000818	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—JAK1—hematologic cancer	0.000188	0.000801	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PRKCG—hematologic cancer	0.000188	0.000801	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SH2B3—hematologic cancer	0.000187	0.000797	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SMARCA4—hematologic cancer	0.000187	0.000797	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GZMB—hematologic cancer	0.000186	0.000792	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CTNNA1—hematologic cancer	0.000182	0.000773	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EIF4EBP1—hematologic cancer	0.00018	0.000769	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HSPB1—hematologic cancer	0.00018	0.000769	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL3—hematologic cancer	0.00018	0.000769	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTHLH—hematologic cancer	0.000178	0.00076	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SDC1—hematologic cancer	0.000178	0.00076	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL2RA—hematologic cancer	0.000175	0.000748	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTGER4—hematologic cancer	0.000174	0.00074	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LCK—hematologic cancer	0.000173	0.000736	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—H3F3A—hematologic cancer	0.000169	0.000722	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKCZ—hematologic cancer	0.000165	0.000702	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CG—hematologic cancer	0.000161	0.000686	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PARP1—hematologic cancer	0.000159	0.000678	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FBXW7—hematologic cancer	0.000156	0.000667	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCR4—hematologic cancer	0.000153	0.000654	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HDAC2—hematologic cancer	0.000153	0.000654	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CBL—hematologic cancer	0.00015	0.000637	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL3—hematologic cancer	0.000148	0.00063	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CG—hematologic cancer	0.000146	0.000623	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTPN1—hematologic cancer	0.000145	0.00062	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTPN11—hematologic cancer	0.000144	0.000612	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RASGRP1—hematologic cancer	0.000143	0.00061	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HSP90AA1—hematologic cancer	0.000143	0.000608	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SYK—hematologic cancer	0.000143	0.000608	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CD—hematologic cancer	0.000142	0.000603	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CREB1—hematologic cancer	0.000139	0.000593	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT1—hematologic cancer	0.000138	0.000586	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL2—hematologic cancer	0.000136	0.00058	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6R—hematologic cancer	0.000136	0.000578	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3R1—hematologic cancer	0.000134	0.000569	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—JAK2—hematologic cancer	0.00013	0.000553	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAP2K1—hematologic cancer	0.000129	0.000551	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GRB2—hematologic cancer	0.000129	0.000548	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CD—hematologic cancer	0.000129	0.000548	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDGFA—hematologic cancer	0.000128	0.000547	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KITLG—hematologic cancer	0.000127	0.000539	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT5A—hematologic cancer	0.000124	0.000527	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CB—hematologic cancer	0.000123	0.000526	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN2B—hematologic cancer	0.000123	0.000522	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3R1—hematologic cancer	0.000121	0.000517	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CD86—hematologic cancer	0.000119	0.000505	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—JAK2—hematologic cancer	0.000118	0.000503	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HES1—hematologic cancer	0.000117	0.000498	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NCOR1—hematologic cancer	0.000116	0.000496	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF1—hematologic cancer	0.000115	0.00049	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CSF2—hematologic cancer	0.000115	0.00049	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FOXO1—hematologic cancer	0.000113	0.000483	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL2—hematologic cancer	0.000113	0.000483	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDGFRB—hematologic cancer	0.000113	0.000482	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CB—hematologic cancer	0.000112	0.000477	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDGFRA—hematologic cancer	0.000111	0.000475	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JAK1—hematologic cancer	0.000111	0.000473	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKCG—hematologic cancer	0.000111	0.000473	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL2RA—hematologic cancer	0.000104	0.000442	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL2—hematologic cancer	0.000103	0.000438	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TERT—hematologic cancer	0.000103	0.000437	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDGFB—hematologic cancer	0.0001	0.000426	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TSC2—hematologic cancer	9.78e-05	0.000417	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGFR3—hematologic cancer	9.41e-05	0.000401	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK14—hematologic cancer	9.31e-05	0.000397	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ESR1—hematologic cancer	9.14e-05	0.000389	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FN1—hematologic cancer	9.02e-05	0.000384	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NFKBIA—hematologic cancer	8.92e-05	0.00038	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BAD—hematologic cancer	8.92e-05	0.00038	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH1—hematologic cancer	8.83e-05	0.000376	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CD80—hematologic cancer	8.65e-05	0.000369	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CG—hematologic cancer	8.64e-05	0.000368	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KIT—hematologic cancer	8.64e-05	0.000368	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—NRAS—hematologic cancer	8.64e-05	0.000368	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTPN11—hematologic cancer	8.48e-05	0.000361	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAPK3—hematologic cancer	8.27e-05	0.000352	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CREB1—hematologic cancer	8.22e-05	0.00035	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BRAF—hematologic cancer	8.12e-05	0.000346	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL2—hematologic cancer	8.04e-05	0.000343	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6R—hematologic cancer	8.02e-05	0.000342	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CREBBP—hematologic cancer	8.01e-05	0.000341	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAP2K1—hematologic cancer	7.64e-05	0.000326	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CD—hematologic cancer	7.59e-05	0.000323	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CA—hematologic cancer	7.52e-05	0.00032	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KRAS—hematologic cancer	7.43e-05	0.000317	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF2—hematologic cancer	7.27e-05	0.00031	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3R1—hematologic cancer	7.17e-05	0.000305	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JAK2—hematologic cancer	6.97e-05	0.000297	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CA—hematologic cancer	6.83e-05	0.000291	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MDM2—hematologic cancer	6.8e-05	0.00029	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CB—hematologic cancer	6.62e-05	0.000282	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MTOR—hematologic cancer	6.62e-05	0.000282	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HRAS—hematologic cancer	6.32e-05	0.000269	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1B—hematologic cancer	6.21e-05	0.000265	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT1—hematologic cancer	6.14e-05	0.000262	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CASP3—hematologic cancer	6.09e-05	0.000259	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL2—hematologic cancer	6.08e-05	0.000259	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—hematologic cancer	6.05e-05	0.000258	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCND1—hematologic cancer	5.92e-05	0.000252	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JUN—hematologic cancer	5.91e-05	0.000252	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1A—hematologic cancer	5.73e-05	0.000244	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTEN—hematologic cancer	5.72e-05	0.000244	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK8—hematologic cancer	5.59e-05	0.000238	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT1—hematologic cancer	5.58e-05	0.000238	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EP300—hematologic cancer	5.45e-05	0.000232	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SRC—hematologic cancer	5.3e-05	0.000226	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—hematologic cancer	5.16e-05	0.00022	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT3—hematologic cancer	5.11e-05	0.000218	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NRAS—hematologic cancer	5.1e-05	0.000217	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK3—hematologic cancer	4.89e-05	0.000208	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MYC—hematologic cancer	4.75e-05	0.000202	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFB1—hematologic cancer	4.74e-05	0.000202	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KRAS—hematologic cancer	4.39e-05	0.000187	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CA—hematologic cancer	4.03e-05	0.000172	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TP53—hematologic cancer	3.9e-05	0.000166	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HRAS—hematologic cancer	3.73e-05	0.000159	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—hematologic cancer	3.57e-05	0.000152	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT1—hematologic cancer	3.3e-05	0.00014	CbGpPWpGaD
